ARSファーマシューティカルズの適時開示・決算・その他

Date: March 7, 2024

ARS Pharmaceuticals, Inc.

/richard lowenthal, m.s., mba.

Richard Lowenthal, M.S., MBA

社長兼最高経営責任者

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

現行レポート

セクション13または15に基づいて(d)

1934年の証券取引所法の

March 7, 2024

報告日（最も古い事象が報告された日)

ARS Pharmaceuticals, Inc.

(チャーターで指定された登録者の正確な名前)

デラウェア

001-39756

81-1489190

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

11682 エル・カミーノ・レアル、スイート120

San Diego, California

92130

(主要経営陣の住所)

(Zip Code)

登録者の電話番号（市外局番を含む(858) 771-9307

Not Applicable

(旧姓または旧住所（前回の報告書から変更された場合）。)

Form 8-Kの提出が、以下の規定のいずれかに基づく登録者の提出義務を同時に満たすことを意図している場合は、以下の該当するチェックボックスをチェックしてください：

☐	証券法に基づく規則425に従った書面によるコミュニケーション（17 cfr 230.425)

☐	取引所法の下でのルール14a-12（17 cfr 240.14a-12）に基づく資料の勧誘。)

☐	取引所法の規則14d-2(b)に基づく開始前のコミュニケーション（17 cfr 240.14d-2(b))

☐	証券取引法の規則13e-4(c)に基づく開始前のコミュニケーション（17 cfr 240.13e-4(c))

法第12条(b)に従って登録された証券：

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

普通株式、1株あたりの額面は0.0001ドル

SPRY

the nasdaq stock market llc

登録者が1933年証券法規則405（本章§230.405）または1934年証券取引法規則12b-2（本章§240.12b-2）で定義される新興成長企業であるかどうかをチェックマークで示す。

Emerging growth company ☒

新興成長企業の場合、登録者が取引所法第13条(a)に従い提供される新規または改訂された財務会計基準に準拠するための移行期間の延長を利用しないことを選択した場合は、チェックマークで示す。☐

Item 2.02

営業成績および財政状態。

2024年3月7日、アルス・ファーマシューティカルズ・インク（以下「当社」）は会社説明会において、2023年12月31日現在、現金および短期投資が約2億2800万ドルあると発表した。

本Current Report on 8-Kの項目2.02に記載された情報は提供されたものであり、1934年証券取引所法改正法（以下「取引所法」）第18条において「提出された」とみなされるものではなく、同法または1933年証券取引所法改正法（以下「証券法」）第11条および第12条(a)(2)の適用を受けるものではありません。本情報は、当社が証券取引委員会に提出した他のいかなる提出書類にも、当該提出書類における特定の参照により明示的に規定されている場合を除き、当該提出書類における一般的な組み込み文言にかかわらず、本日日付の前後を問わず、参照により組み込まれるものとはみなされません。

Item 7.01.

Regulation FD Disclosure.

2024年3月7日、当社は投資家、アナリスト、その他との会合で使用する会社説明資料を更新した。同プレゼンテーションは当社ウェブサイトを通じて入手可能であり、そのコピーは本Current Report on Form 8-Kの別紙99.1として添付され、参照により本書に組み込まれている。

本Current Report on 8-Kの項目7.01に記載された情報は、別紙99.1を含め、提供されたものであり、証券取引法第18条において「提出された」とみなされるものではなく、同条または証券取引法第11条および第12条(a)(2)の適用を受けるものではありません。この情報は、証券取引委員会に提出された他のいかなる提出書類にも、当該提出書類における特定の参照により明示的に規定されている場合を除き、当該提出書類における一般的な組み込み文言にかかわらず、本日付の前後にかかわらず、参照により組み込まれるものとはみなされません。

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits


ExhibitNo.		Description

99.1		2024年3月7日付会社説明会。

104		cover page interactive data file (インラインxbrl文書内に埋め込まれている)。

SIGNATURES

1934年証券取引所法（Securities Exchange Act of 1934）の要件に従い、登録者は本報告書に正式に権限を付与された署名者により、登録者を代表して署名させた。

EX-99.1 2 d809686dex991.htm EX-99.1 EX-99.1

Exhibit 99.1 neffy Investor Day March 7, 2024

Forward Looking Statements Statements in this presentation that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation include, without limitation, statements regarding: ARS Pharma’s plan to file its NDA early in the second quarter of 2024, with an anticipated PDUFA action date and launch of neffy, if approved, in the second half of 2024; the timing of the EMA’s decision and submissions to other foreign regulatory authorities; the potential market, demand and expansion opportunities for neffy; ARS Pharma’s expected competitive position; whether the results will be sufficient to demonstrate that neffy is at least as effective as injectable epinephrine; the timelines for potential regulatory filings, approvals and commercialization of neffy in ex-US regions; ARS Pharma’s marketing and commercialization strategies, including potential partnerships in foreign jurisdictions; potential benefits of neffy, if approved, including the likelihood that doctors will prescribe neffy and that allergy patients and caregivers will choose to carry and dose neffy compared to needle-bearing options; the expectation of neffy attaining coverage, including without restriction for 80% of commercial lives within a year of launch; ARS Pharma’s anticipated cash, cash equivalents and short-term investments on hand upon any future approval and launch of neffy; the expected size, composition and reach of ARS Pharma’s sales force; the availability and functionality of neffyExperience and neffyConnect; the anticipated pricing and co-pay buydown; the anticipated timing and costs of future studies and commercialization efforts, and their impact on operating runway; ARS Pharma’s projected operating runway; expected intellectual property protection; and any statements of assumptions underlying any of the foregoing. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipate,” “could,” “demonstrate,” “expect,” “indicate,” “may,” “plan,” “potential,” “will” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon ARS Pharma’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: the PDUFA target action date may be further delayed due to various factors outside ARS Pharma’s control; the ability to obtain and maintain regulatory approval for neffy; the results of the new clinical trial may not support the approval of neffy; results from clinical trials may not be indicative of results that may be observed in the future; potential safety and other complications from neffy; the labelling for neffy, if approved; the scope, progress and expansion of developing and commercializing neffy; potential for payers to delay, limit, or deny coverage for neffy; the size and growth of the market therefor and the rate and degree of market acceptance thereof vis-à-vis intramuscular injectable products; ARS Pharma’s ability to protect its intellectual property position; uncertainties related to capital requirements; and the impact of government laws and regulations. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” in ARS Pharma’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, filed with the Securities and Exchange Commission (“SEC”) on November 9, 2023. This and other documents ARS Pharma files with the SEC can also be accessed on ARS Pharma’s website at ir.ars-pharma.com by clicking on the link “Financials & Filings” under the “Investors & Media” tab. The forward-looking statements included in this presentation are made only as of the date hereof. ARS Pharma assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Today’s Speakers ARS Management Key Opinion Leaders Richard Lowenthal, M.S., MSEL Jonathan Spergel, M.D., Ph.D. Chief Executive Officer, Co-Founder Chief of Allergy Program Led FDA approvals for multiple Children’s Hospital of Philadelphia nasal spray products 25+ years of experience Eric Karas Thomas B. Casale, M.D. Chief Commercial Officer ® Professor of Medicine & Pediatrics Led Narcan commercial ops at Chief, Allergy & Immunology Emergent/Adapt, and Auxilium specialty University of South Florida 25+ years of experience 3

Potential to Transform the Treatment of Type I Allergic Reactions • neffy®: first potential “no needle, no injection” solution for Type I allergic reactions to address an unmet market need • Registration program demonstrates comparable PK and PD, without risk of needle-related safety concerns, fear and hesitation • Rapid and statistically significant response on PD surrogates for efficacy (SBP, HR) observed even 1 minute after dosing with neffy vs. injection • Significant opportunity to disrupt current epinephrine injectables market • Completed repeat dose NAC study requested by FDA in Sept 2023 CRL • NDA on track to respond to FDA CRL by early Q2 2024, with FDA action date and potential US launch in H2 2024 • Potential multi-billion-dollar market driven by HCP and consumer preference and adoption • NCE-like IP exclusivity potential until at least 2038 • $228 million in cash and short-term investments as of 12/31/2023 with an anticipated $195 million at anticipated FDA action in H2 2024 4

What We Will Cover Today Unmet need in type I allergic reactions including anaphylaxis Dr. Jonathan Spergel neffy clinical profile, registrational studies Richard Lowenthal neffy benefit-risk for type I allergic reactions including anaphylaxis Dr. Thomas Casale US market opportunity and commercialization strategy Eric Karas 5

Unmet Need / Current Challenges Vast Majority of Type I Allergy Patients Face Significant Limitations with Current Treatment Options NO TREATMENT REFUSAL OF DELAY IN USER ERROR PROBLEM AVAILABLE TREATMENT TREATMENT IN TREATMENT ONLY 10% - 20% of 1 ~40% - 60% of ~50% of patients carry ~25% - 60% do not 23% - 35% fail to patients with active 2 7 (<20% carry two) , 1,3 5, 6 4 Rx use as indicated patients delay administer dose correctly EASIER AND MORE RELIABLE neffy NO NEEDLE SMALL CONSISTENT DOSING SOLUTIONS NO INJECTION • 99.999% delivery of • Fits in your pocket; effective dose in can carry more than 1 • Rapid administration • 0% critical dosing errors reliability testing; no without a needle in registration • ~10% of cases require inhalation required self-administration study repeat doses of • No risk of needle-related 2 1 • 24 month shelf-life at injuries; lacerations or epinephrine • High bioavailability, low 2 room temperature, with cardiotoxic blood vessel mg dose of neffy achieves up to 3 months at high injections comparable PK without o temperatures (122 F) overexposure risk • Less hesitation to dose 6 References: 1. Warren CM, et al. Ann Allergy Asthma Immunol. 2018. 2. Rooney E, et al. Poster Presentation at ACAAI 2022 (Louisville, KY). 3. Brooks C, et al. Ann Allergy Asthma Immunol. 2017. 4. El Turki A, et al. Emerg Med J. 2017. 5. Asthma and Allergy Foundation of American Patient Survey Report 2019. 6. Mehta GD, et al. Expert Rev Clin Immunol. 2023. 7. ARS company estimates based on IQVIA data and references 1 through 6.

Significant Catalysts for neffy in 2024 o US NDA response to CRL by early Q2 2024 FDA o PDUFA action date anticipated in H2 2024 o EMA decision (CHMP Opinion) expected by mid-2024 EMA o China NDA filing expected by YE 2024 o Japan NDA filing expected by YE 2024 o Planning in progress for filing in other major ex-US regions including Canada o Expansion opportunities • Positive data from Phase 2 chronic urticaria study reported in Feb 2024 • Initiation of Phase 2b outpatient urticaria study 7

Type I Allergies & Unmet Needs Jonathan M. Spergel, M.D., Ph.D. Professor of Pediatrics Chief of the Allergy Program Children’s Hospital of Philadelphia

Type I Allergic Reactions: Systemic Hypersensitivity Reaction More than 500,000 ER visits ~40 Million people in each year due to systemic Type I allergic US with systemic Type I allergic 1 2 reactions , costing an average of $1600+ per visit reaction to allergens Other Type I allergy indications Significant co-morbidities and symptomatic Caused by exposure to a specific allergen, (e.g. urticaria flares) impact on quality of life. most commonly food, venom, drugs References: 1. Carillo-Martin I, et al. J Allergy Clin Immunol Pract 2020. 2. BlueCross BlueShield of America. Childhood Allergies in America 2018 9 Images reproduced with permission

Mucosal Respiratory Cardiac GI Anaphylaxis Diagnosis Criteria and Symptoms 2-14 Symptoms (>2%) reported during US anaphylaxis events 0% 20% 40% 60% 80% 100% Urticaria or Angioedema Urticaria Flushing Pruritus Angioedema (e.g. face, lips, tongue or larynx) Intraoral Edema or Tongue Swelling Laryngeal Edema Throat pruritus Orophyarngeal Edema Difficulty Breathing / Dyspnea Throat Tightness Wheezing Bronchospasm Hoarseness Cough Chest tightness / Chest pain Respiratory failure Stridor Nasal symptoms / rhinitis Tachycardia Presyncope / Dizziness /Light headedness Hypotension Confusion/somnolence Loss of consciousness Dysphagia Vomiting / Emesis Diarrhea + Abdominal Pain Nausea Abdominal pain or cramping Diarrhea References: 1. Shaker MS, et al. J Allergy Clin Immunol. 2020. 2. Pistiner M, et al. J Allergy Clin Immunol Pract. 2021. 3. Jalil M, et al. Abstract at AAAAI 2020 Virtual Meeting. 4. Gonzelez-Estrada A, et al. Ann Allergy Asthma Immunol. 10 2018. 5. Lee S, et al. J Allergy Clin Immunol. 2017. 6. Lee S, et al. J Allergy Clin Immunol Pract. 2014. 7. Manivannan V, et al. Am J Emerg Med. 2014. 8. Wood RA, et al. J Allergy Clin Immunol 2014. 9. Walsh KE, et al. Pharmacoepidemiol Drug Saf 2013. 10. Decker WW, et al. J Allergy Clin Immunol. 2008. 11. Ross MP, et al. J Allergy Clin Immunol. 2008. 12. Webb LM & Lieberman P. Ann Allergy Asthma Immunol. 2006. 13. Ditto AM, et al. Ann Allergy Asthma Immunol. 1996. 14. Rudders SA, et al. Pediatrics. 2010. Note that some publications do not specify angioedema symptom subtype. Angioedema subtype frequency aggregated when reported.

Most frequently reported symptoms are difficulty breathing, angioedema (face, lips, tongue, larynx) and urticaria (hives) References: 1. LoVerde D, et al. Chest. 2018. 2. Images reproduced with permission 11

Epinephrine: Well Known Mechanism of Action Adrenergic Pharmacological Effect Clinical Effect Receptor of Epinephrine of Epinephrine • Stabilizes mast cells and basophils - • Reverses pathological histamine cascade Inhibits inflammatory mediators • Increase in bronchial airflow β 2 • Relaxation of bronchial smooth muscles • Increases blood to skeletal muscle • Vasodilation in skeletal vasculature β • Increases blood pressure and heart rate • Relieves hypotension and shock 1 • Increases systolic blood pressure • Relieves hypotension and shock • Causes blood vessel constriction α 1 • Relieves upper airway obstruction • Decreases mucosal edema Receptor Sensitivity 12

Second Dose Demonstrates Similar Efficacy Between IM and Autoinjectors (the only FDA approved products today) ~90% resolution on first dose 12% • Analysis of 12 studies with 100% autoinjector (≥ 80% EpiPen) or 10% 9.3% 100% IM-needle-and-syringe use in 1-11 community or ED setting 8% • Differences in PK profile across 6% products do not impact efficacy based on need for repeat dosing to resolve symptoms 4% 2% 0% IM Needle-in-Syringe Autoinjector % r equiring second dose reactions reactions 11 n = 570 n = 799 References: 1. Patel N, et al. J Allergy Clin Immunol. 2021. 2. Kahveci M, et al. Pediatr Allergy Immunol. 2020. 3. Oya S, et al. J Emerg Med. 2020. 4. Kondo A, et al. Air Med J. 2018. 5. Cardona V, et al. Int Arch Allergy 13 Immunol. 2017. 6. Arkwright PD. J Allergy Clin Immunol. 2008. 7. Gold MS & Sainsbury R. J Allergy Clin Immunol. 2020. 8. Noimark L, et al. Clin Exp Allergy. 2011. 9. Soller L, et al. J Allergy Clin Immunol Pract. 2019. 10. Webb LM & Lieberman P. Ann Allergy Asthma Immunol. 2006. 11. White MV, et al. Allergy Ashm Proc. 2015; note that this publication reports data on 636 reactions treated exclusively with EpiPen Treated Reactions Requiring Second Epinephrine Dose (%)

Prompt Treatment with Epinephrine is Critical ANTIGEN EXPOSURE Consequence of Delayed Treatment Risk Factor 1 Abnormal vitals (HR, SBP, Respiration) p<0.001 Patients / Caregivers wait 2 Repeat Epinephrine Doses OR = 5.0 up to 18 minutes 3 Hospitalization (500,000 ER visits / yr) HR = 4.0 to dose epinephrine 4 Biphasic anaphylaxis OR = 3.4 5 Fatality References: 1. Andrew E, et al. Prehosp Emerg Care. 2018. 2. Hochstadter E, et al. J Allergy Clin Immunol. 2016. 3. Fleming JT, et al. J Allergy Clin Immunol Pract. 2015. 4. Liu X, et al. J Allergy Clin Immunol Pract. 2020. 5. Turner PJ, 14 et al. J Allergy Clin Immunol. 2017.

% dosed with epinephrine in b community setting (pre-ED) Only ~40% of ER Anaphylaxis Patients are Dosed with Epinephrine Pre-Arrival in the Community Setting Median Year of Study Period 15 References: 1. Mehta GD, et al. Expert Rev Clin Immunol. 2023. Percentage Treated with Epinephrine

Delays in Treatment with Epinephrine are Principally Due to Autoinjector Limitations and Accompanying Patient Reluctance ~40% of patients do not >40% of patients do not fill or refill 40% 2 1 40% administer epinephrine at all their epinephrine prescription >50% of parents are afraid or 55%-60% don’t consistently somewhat afraid to administer 50% 2-4 60% carry epinephrine 5 their child’s epinephrine ~20% of patients Patients that Do Not ~70% of patients 20% 70% with Training Without Training 7 Administer Correctly References: 1. Data on File. ARS Pharmaceuticals. 2023. 2. Warren CM, et al. Ann Allergy Asthma Immunol. 2018. 3. Brooks C, et al. Ann Allergy Asthma Immunol. 2017. 4. Curtis C, et al. Ann Allergy Asthma Immunol. 2014. 5. Chad L, 16 et al. Eur J Allergy Clin Immunol. 2013. 6. Sicherer SH, et al. Pediatrics. 2000. 7. El Turki A, et al. Emerg Med J. 2017.

Needle-Related Safety Risks & Use Errors Needle-related risks defined in labeling for all autoinjectors Ø Lacerations and bone injections Ø IV bolus injection (blood vessel injections) – likely result in most serious AEs Accidental self-injection into extremity by patient or caregiver 1 Ø ~ 3,500 events per year reported Ø Requires immediate medical attention (treatment in ER typical) 2 Injection site pain, infection and other reactions Wet injections (withdraw needle too quickly) and other dosing errors 3,4,5,6,7,8,9 User errors and device malfunctions References: 1. Anshien M, et al. Am J Ther. 2019. 2. Guerlain S, et al. Ann Allergy Asthma Immunol. 2011. 3. El Turki A, et al. Emerg Med J. 2017. 4. Moss RB, et al. Ann Allergy Asthma Immunol. 2018. 5. 17 Sanofi. Auvi-Q Recall. October 2015. 6. FDA. EpiPen and EpiPen Jr Recall. March 2017. 7. FDA. EpiPen auto-injector errors related to device malfunctions and user administration. March 2020. 8. FDA. Amneal and Impax Laboratories epinephrine auto-injector device malfunctions. June 2020. 9. FDA. Recall of Symjepi (epinephrine) injection for potential manufacturing defect. March 2022.

会社

会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無

会社

会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミア

会社

会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初

会社

会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。初めての方には「30日間の無料体験」実施中！会社開示情報をすべてご覧になるには株探プレミアムの登録が必要です。

会社